CLB Stock - Core Laboratories N.V.
Unlock GoAI Insights for CLB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $523.85M | $509.79M | $489.74M | $470.25M | $487.27M |
| Gross Profit | $88.37M | $94.05M | $78.92M | $83.84M | $102.13M |
| Gross Margin | 16.9% | 18.4% | 16.1% | 17.8% | 21.0% |
| Operating Income | $58.56M | $54.64M | $41.52M | $45.26M | $-76,805,000 |
| Net Income | $31.40M | $36.67M | $19.45M | $19.73M | $-97,637,000 |
| Net Margin | 6.0% | 7.2% | 4.0% | 4.2% | -20.0% |
| EPS | $0.67 | $0.79 | $0.42 | $0.43 | $-2.18 |
Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 12th 2025 | Citigroup | Upgrade | Neutral | $16← $15 |
| June 30th 2023 | Citigroup | Downgrade | Sell | $21← $22 |
| April 18th 2023 | BofA Securities | Downgrade | Underperform | $21.5 |
| January 9th 2023 | BofA Securities | Upgrade | Neutral | - |
| October 7th 2022 | Citigroup | Upgrade | Neutral | $17← $24 |
| September 26th 2022 | Morgan Stanley | Downgrade | Underweight | $20 |
| April 18th 2022 | Piper Sandler | Downgrade | Underweight | $21.3← $19.5 |
Earnings History & Surprises
CLBEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 4, 2026 | $0.20 | — | — | — |
Q4 2025 | Oct 22, 2025 | $0.19 | $0.22 | +15.8% | ✓ BEAT |
Q3 2025 | Jul 23, 2025 | $0.18 | $0.19 | +5.6% | ✓ BEAT |
Q2 2025 | Apr 23, 2025 | $0.15 | $0.14 | -6.7% | ✗ MISS |
Q1 2025 | Jan 29, 2025 | $0.23 | $0.22 | -4.3% | ✗ MISS |
Q4 2024 | Oct 23, 2024 | $0.23 | $0.25 | +8.7% | ✓ BEAT |
Q3 2024 | Jul 24, 2024 | $0.21 | $0.22 | +4.8% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $0.16 | $0.19 | +18.8% | ✓ BEAT |
Q1 2024 | Jan 31, 2024 | $0.20 | $0.19 | -5.0% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $0.22 | $0.22 | 0.0% | = MET |
Q3 2023 | Jul 26, 2023 | $0.20 | $0.21 | +5.0% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $0.17 | $0.19 | +11.8% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $0.19 | $0.20 | +5.3% | ✓ BEAT |
Q4 2022 | Oct 26, 2022 | $0.15 | $0.18 | +20.0% | ✓ BEAT |
Q3 2022 | Jul 27, 2022 | $0.14 | $0.12 | -14.3% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | $0.06 | $0.08 | +33.3% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $0.20 | $0.20 | 0.0% | = MET |
Q4 2021 | Oct 27, 2021 | $0.19 | $0.18 | -5.3% | ✗ MISS |
Q3 2021 | Jul 28, 2021 | $0.19 | $0.18 | -5.3% | ✗ MISS |
Q2 2021 | Apr 21, 2021 | $0.13 | $0.15 | +15.4% | ✓ BEAT |
Latest News
Core Laboratories shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 sales guidance above estimates.
📈 PositiveCore Laboratories Sees Q4 GAAP EPS $0.18-$0.22 vs $0.19 Est; Sees Sales $132.000M-$136.000M vs $128.575M Est
📈 PositiveCore Laboratories Q3 Adj. EPS $0.22 Beats $0.19 Estimate, Sales $134.521M Beat $131.300M Estimate
📈 PositiveCore Laboratories Acquires Solintec; Amount. Not Disclosed
📈 PositiveFrequently Asked Questions about CLB
What is CLB's current stock price?
What is the analyst price target for CLB?
What sector is Core Laboratories N.V. in?
What is CLB's market cap?
Does CLB pay dividends?
Similar Stocks
Energy SectorExplore stocks similar to CLB for comparison